Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.49 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701615 | 0.89 | GPR119 (0.52) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL10246536 | 0.89 | CCR5 (0.49) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL700251 | 0.88 | CCR5 (0.57) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL10282907 | 0.87 | CCR5 (0.50) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL10246201 | 0.86 | GPR119 (0.50) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL10246265 | 0.86 | NAMPT (0.48) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL703519 | 0.86 | CCR5 (0.46) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL13658176 | 0.86 | NAMPT (0.47) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL3326591 | 0.86 | GPR119 (0.51) | CCR5NAMPTGPR119TACR1OPRD1 | |
| SCHEMBL703385 | 0.85 | CCR5 (0.56) | CCR5NAMPTGPR119TACR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2262791-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | CCR5 1218/4885NAMPT 2136/4885GPR119 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.